Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.

[1]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[2]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[3]  E. Reinherz,et al.  Enhancement of natural killer function through activation of the T11 E rosette receptor. , 1987, The Journal of clinical investigation.

[4]  N. Damle,et al.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. , 1986, Journal of immunology.

[5]  J. Talmadge,et al.  Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes. , 1986, Cellular immunology.

[6]  C. Riccardi,et al.  Generation of mouse natural killer (NK) cell activity: Effect of interleukin‐2 (IL‐2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells , 1986, International journal of cancer.

[7]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[8]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[9]  S. Rosenberg,et al.  Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. , 1986, Journal of immunology.

[10]  C. Riccardi,et al.  Low frequency of NK‐cell progenitors and development of suppressor cells in IL‐2‐dependent cultures of spleen cells from low NK‐reactive SJL/J mice , 1986, International journal of cancer.

[11]  J. Ritz,et al.  A subset of natural killer cells in peripheral blood displays a mature T cell phenotype , 1986, The Journal of experimental medicine.

[12]  C. Balch,et al.  Lysis of human solid tumor cells by lymphokine-activated natural killer cells. , 1986, Journal of immunology.

[13]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[14]  J. Gray,et al.  Functional studies on the precursors of human lymphokine-activated killer cells. , 1985, Cellular immunology.

[15]  E. Reinherz,et al.  The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. , 1985, Journal of immunology.

[16]  S. Rosenberg,et al.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. , 1985, Journal of immunology.

[17]  Craig W. Reynolds,et al.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. , 1985, Journal of immunology.

[18]  J. Ritz,et al.  Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. , 1985, The Journal of clinical investigation.

[19]  C. Balch,et al.  Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. , 1985, Journal of immunology.

[20]  S. Golub,et al.  Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. , 1985, Journal of immunology.

[21]  A. Uchida,et al.  Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor. , 1984, Journal of the National Cancer Institute.

[22]  A. Uchida,et al.  Natural killer cell activity and autologous tumor killing activity in cancer patients: overlapping involvement of effector cells as determined in two-target conjugate cytotoxicity assay. , 1984, Journal of the National Cancer Institute.

[23]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[24]  B. V. van Krimpen,et al.  Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. , 1984, Journal of immunology.

[25]  R. Hopkins,et al.  Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. , 1984, Journal of immunology.

[26]  S. Rosenberg,et al.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. , 1984, Cancer research.

[27]  K. Shortman,et al.  Loss of specificity in cytolytic T lymphocyte clones obtained by limit dilution culture of Ly-2+ T cells. , 1984, Journal of immunology.

[28]  G F Babcock,et al.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. , 1983, Journal of immunology.

[29]  A. Uchida,et al.  Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. , 1983, Journal of the National Cancer Institute.

[30]  Craig W. Reynolds,et al.  In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. , 1983, Journal of immunology.

[31]  A. Uchida,et al.  Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions , 1983, International journal of cancer.

[32]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells , 1983, The Journal of experimental medicine.

[33]  E. Reinherz,et al.  Phenotypic and functional heterogeneity of human cloned natural killer cell lines , 1983, Nature.

[34]  C. Riccardi,et al.  Modulation of IL 2-dependent growth of mouse NK cells by interferon and T lymphocytes. , 1983, Journal of immunology.

[35]  M. Toribio,et al.  Induction of natural killer‐like cytotoxicity in cultured human thymocytes , 1983, European journal of immunology.

[36]  N. Sidell,et al.  Interleukin 2 and stimulator lymphoblastoid cells will induce human thymocytes to bind and kill K562 targets , 1982, The Journal of experimental medicine.

[37]  R. Wiltrout,et al.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice , 1982, International journal of cancer.

[38]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[39]  Craig W. Reynolds,et al.  Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. , 1981, Journal of immunology.

[40]  C. Henney,et al.  Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. , 1981, Journal of immunology.

[41]  J. Ortaldo,et al.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells , 1981, The Journal of experimental medicine.

[42]  P. Levine,et al.  Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. , 1974, Journal of the National Cancer Institute.

[43]  P. Levine,et al.  Lymphocyte cytotoxicity reactions to leukemia‐associated antigens in identical twins , 1972, International journal of cancer.

[44]  R. J. Harris.  Proceedings of the 9th International Cancer Congress , 1967, UICC Monograph Series.